Selumetinib in Cancers With BRAF Mutations

NCT00888134 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm

Interventions

DRUG: Selumetinib

Sponsor

National Cancer Institute (NCI)